Top

Published in:

01-09-2018 | Laboratory Investigation

Pre- and early postoperative GFAP serum levels in glioma and brain metastases

Authors: Peter Baumgarten, Johanna Quick-Weller, Florian Gessler, Marlies Wagner, Julia Tichy, Marie-Therese Forster, Christian Foerch, Volker Seifert, Michel Mittelbronn, Christian Senft

Published in: Journal of Neuro-Oncology | Issue 3/2018

Abstract

Subject

To date there is no established tumor marker for the clinical follow-up of glioblastoma, WHO grade IV, (GBM) which constitutes the most frequent and malignant primary brain tumor. However, since there is promising data that the serum glial fibrillary acidic protein (sGFAP) may serve as a biomarker for glial brain tumors, this prospective study aimed at evaluating the diagnostic relevance of perioperative changes in sGFAP levels for the assessment of residual glial tumor tissue in patients undergoing surgery of intracerebral tumors.

Methods

Serum GFAP was measured using an electrochemiluminometric immunoassay (ElecsysR GFAP prototype test, Roche Diagnostics, Penzberg/Germany) in 32 prospectively recruited patients between September 2009 and August 2010. Twenty-five were diagnosed with glioma and seven with brain metastases (BM). We assessed sGFAP levels prior to and at different time points during the early postoperative phase until patient discharge.

Results

There were only significant differences in the pre-operative sGFAP levels of patients with gliomas compared to BM (0.18 vs. 0.08 µg/l; p = 0.0198, Welch’s t-Test). Even though there was an increase of sGFAP after surgery, there were no significant differences between glioma and BM patients at any other time point. Peak sGFAP levels where reached on postoperative day 1 followed by a slight decrease, but not reaching pre-operative levels until postop day 7. There was no significant correlation between postoperative glioma tumor volume and sGFAP levels in univariate analyses.

Conclusion

According to our data sGFAP does not appear to be suitable to detect residual glioma tissue in the acute postoperative phase.

Available only for authorised users

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMed

Barnholtz-Sloan JS, Yu C, Sloan AE, Vengoechea J, Wang M, Dignam JJ et al (2012) A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro-Oncology. https://doi.org/10.1093/neuonc/nos087 PubMedPubMedCentralCrossRef

Khalifa J, Tensaouti F, Chaltiel L, Lotterie J-A, Catalaa I, Sunyach MP et al (2016) Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation. Eur Radiol. https://doi.org/10.1007/s00330-016-4234-5 PubMedCrossRef

Buchmann N, Kläsner B, Gempt J, Bauer JS, Pyka T, Delbridge C et al (2016) (18) F-fluoroethyl-L-thyrosine (FET) PET to delineate tumor residuals after glioblastoma resection: a comparison to standard postoperative MRI. World Neurosurg. https://doi.org/10.1016/j.wneu.2016.02.032 CrossRefPubMed

Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M (2016) Gadolinium-based contrast agent accumulation and toxicity: an update. Am J Neuroradiol. https://doi.org/10.3174/ajnr.A4615 CrossRefPubMed

Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834–841. https://doi.org/10.1148/radiol.13131669 CrossRefPubMed

Siddall JK, Shetty SD, Cooper EH (1986) Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate. Clin Chem 32:2040–2043PubMed

Seamonds B, Yang N, Anderson K, Whitaker B, Shaw LM, Bollinger JR (1986) Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. Urology 28:472–479CrossRefPubMed

Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909–916. https://doi.org/10.1056/NEJM198710083171501 CrossRefPubMed

10.

Eng LF (1986) Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol 8:203–214CrossRef

11.

Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO et al (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845. https://doi.org/10.1158/1078-0432.ccr-06-0181 PubMedCrossRef

12.

Kiviniemi A, Gardberg M, Frantzén J, Parkkola R, Vuorinen V, Pesola M et al (2015) Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival. J Neuro-Oncol 124:237–245. https://doi.org/10.1007/s11060-015-1829-7 CrossRef

13.

Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res 25:1439–1451CrossRefPubMed

14.

Yung WK, Luna M, Borit A (1985) Vimentin and glial fibrillary acidic protein in human brain tumors. J Neuro-Oncol 3:35–38CrossRef

15.

Jung CS, Foerch C, Schänzer A, Heck A, Plate KH, Seifert V et al (2007) Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130:3336–3341. https://doi.org/10.1093/brain/awm263 CrossRefPubMed

16.

Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V (2007) Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand 116:380–384. https://doi.org/10.1111/j.1600-0404.2007.00889.x CrossRefPubMed

17.

Lyubimova NV, Toms MG, Popova EE, Bondarenko YV, Krat VB, Kushlinskii NE (2001) Neurospecific proteins in the serum of patients with brain tumors. Bull Exp Biol Med 150:732–734CrossRef

18.

Foerch C, Niessner M, Back T, Bauerle M, De Marchis GM, Ferbert A et al (2012) Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem 58:237–245. https://doi.org/10.1373/clinchem.2011.172676 CrossRefPubMed

19.

Tichy J, Spechtmeyer S, Mittelbronn M, Hattingen E, Rieger J, Senft C et al (2015) Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. J Neuro-Oncol 126:361–369. https://doi.org/10.1007/s11060-015-1978-8 CrossRef

20.

Husain H, Savage W, Grossman SA, Ye X, Burger PC, Everett A et al (2012) Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. J Neuro-Oncol 109:123–127. https://doi.org/10.1007/s11060-012-0874-8 CrossRef

21.

Raheja A, Sinha S, Samson N, Bhoi S, Subramanian A, Sharma P et al (2016) Serum biomarkers as predictors of long-term outcome in severe traumatic brain injury: analysis from a randomized placebo-controlled Phase II clinical trial. J Neurosurg. https://doi.org/10.3171/2015.6.JNS15674 CrossRefPubMed

22.

Condorelli DF, Dell’Albani P, Kaczmarek L, Messina L, Spampinato G, Avola R et al (1990) Glial fibrillary acidic protein messenger RNA and glutamine synthetase activity after nervous system injury. J Neurosci Res 26:251–257. https://doi.org/10.1002/jnr.490260216 CrossRefPubMed

23.

Mucke L, Oldstone MB, Morris JC, Nerenberg MI (1991) Rapid activation of astrocyte-specific expression of GFAP-lacZ transgene by focal injury. N Biologist 3:465–474

24.

Arai N (1992) The role of swollen astrocytes in human brain lesions after edema–an immunohistochemical study using formalin-fixed paraffin-embedded sections. Neurosci Lett 138:56–58CrossRefPubMed

25.

Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA et al (2013) Invasion patterns in brain metastases of solid cancers. Neuro-Oncol 15:1664–1672. https://doi.org/10.1093/neuonc/not112 CrossRefPubMedPubMedCentral

26.

Neves S, Mazal PR, Wanschitz J, Rudnay AC, Drlicek M, Czech T et al (xxxx) Pseudogliomatous growth pattern of anaplastic small cell carcinomas metastatic to the brain. Clin Neuropathol 20:38–42

27.

Shaffrey ME, Mut M, Asher AL, Burri SH, Chahlavi A, Chang SM et al (2004) Brain metastases. Curr Prob Surg 41:665–741. https://doi.org/10.1067/j.cpsurg.2004.06.001 CrossRef

28.

Baumert BG, Rutten I, Dehing-Oberije C, Twijnstra A, Dirx MJM, Debougnoux-Huppertz RMTL. et al (2006) A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiation Oncol Biol Phys 66:187–194. https://doi.org/10.1016/j.ijrobp.2006.03.050 CrossRef

29.

Kamp MA, Dibué M, Niemann L, Reichelt DC, Felsberg J, Steiger H-J et al (2012) Proof of principle: supramarginal resection of cerebral metastases in eloquent brain areas. Acta Neurochir 154:1981–1986. https://doi.org/10.1007/s00701-012-1463-5 CrossRefPubMed

30.

Kamp MA, Dibué M, Santacroce A, Zella SM, Niemann L, Steiger H-J et al (2013) The tumour is not enough or is it? Problems and new concepts in the surgery of cerebral metastases. Ecancermedicalscience 7:306. https://doi.org/10.3332/ecancer.2013.306 PubMedPubMedCentralCrossRef

31.

Kamp MA, Rapp M, Slotty PJ, Turowski B, Sadat H, Smuga M et al (2015) Incidence of local in-brain progression after supramarginal resection of cerebral metastases. Acta Neurochir 157:905-10-1. https://doi.org/10.1007/s00701-015-2405-9 CrossRef

Title: Pre- and early postoperative GFAP serum levels in glioma and brain metastases
Authors: Peter Baumgarten
Johanna Quick-Weller
Florian Gessler
Marlies Wagner
Julia Tichy
Marie-Therese Forster
Christian Foerch
Volker Seifert
Michel Mittelbronn
Christian Senft
Publication date: 01-09-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2898-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pre- and early postoperative GFAP serum levels in glioma and brain metastases

Abstract

Subject

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Subject

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Earliest radiological progression in glioblastoma by multidisciplinary consensus review

Retrospective study of nivolumab for patients with recurrent high grade gliomas

Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma

G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity

A unique presentation of an adolescent with disseminated atypical choroid plexus papilloma

Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy